文献速递血脂与心血管预防

口服PCSK9抑制剂MK-0616的2b期随机试验

Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616.
PubMed 文献 · J Am Coll Cardiol · 2023-03-06

该2b期随机双盲安慰剂对照多中心试验纳入381例高胆固醇血症成人,评估MK-0616(6、12、18、30 mg每日一次)的疗效与安全性。第8周LDL-C较基线的最小二乘均值百分比变化在所有剂量组均显著优于安慰剂(P<0.001),降幅达41.2%至60.9%。不良事件发生率与安慰剂相似,因不良事件停药者极少。

要点

  • MK-0616各剂量(6–30 mg)第8周LDL-C降幅均显著优于安慰剂(P<0.001)。
  • 最高剂量30 mg安慰剂校正后LDL-C降幅达60.9%。
  • 不良事件发生率与安慰剂相似,因不良事件停药罕见。

核心结论

  • MK-0616在第8周显示出统计学显著且稳健的剂量依赖性LDL-C降低,安慰剂校正后降幅最高达60.9%,8周治疗及额外8周随访期间耐受良好。

研究设计与样本

  • 2b期随机双盲安慰剂对照多中心试验,计划纳入375例动脉粥样硬化性心血管疾病风险范围广泛的成人高胆固醇血症患者,按1:1:1:1:1随机分配至MK-0616 6、12、18或30 mg每日一次或匹配安慰剂。
  • 实际随机381例,女性占49%,中位年龄62岁;380例接受治疗。

主要发现

  • 第8周LDL-C较基线的最小二乘均值百分比变化:6 mg为-41.2%,12 mg为-55.7%,18 mg为-59.1%,30 mg为-60.9%,所有剂量与安慰剂比较P<0.001。
  • 不良事件发生率:MK-0616组为39.5%至43.4%,安慰剂组为44.0%。
  • 因不良事件停药者在任何治疗组中均不超过2例。

临床怎么用

  • 口服PCSK9抑制剂MK-0616可在8周内显著降低高胆固醇血症患者的LDL-C,且不良事件发生率与安慰剂相似,因不良事件停药罕见。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: MK-0616 is an oral macrocyclic peptide inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) in development for the treatment of hypercholesterolemia. OBJECTIVES: This Phase 2b, randomized, double-blind, placebo-controlled, multicenter trial aimed to evaluate the efficacy and safety of MK-0616 in participants with hypercholesterolemia. METHODS: This trial was planned to include 375 adult participants with a wide range of atherosclerotic cardiovascular disease risk. Participants were assigned randomly (1:1:1:1:1 ratio) to MK-0616 (6, 12, 18, or 30 mg once daily) or matching placebo. The primary endpoints included percentage change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 8 and the proportion of participants with adverse events (AEs) and study intervention discontinuations due to AEs; participants were monitored for AEs for an additional 8 weeks after the 8-week treatment period. RESULTS: Of the 381 participants randomized, 49% were female, and the median age was 62 years. Among 380 treated participants, all doses of MK-0616 demonstrated statistically significant (P < 0.001) differences in least squares mean percentage change in LDL-C from baseline to Week 8 vs placebo: -41.2% (6 mg), -55.7% (12 mg), -59.1% (18 mg), and -60.9% (30 mg). AEs occurred in a similar proportion of participants in the MK-0616 arms (39.5% to 43.4%) as placebo (44.0%). Discontinuations due to AEs occurred in 2 or fewer participants in any treatment group. CONCLUSIONS: MK-0616 demonstrated statistically significant and robust, dose-dependent placebo-adjusted reductions in LDL-C at Week 8 of up to 60.9% from baseline and was well tolerated during 8 weeks of treatment and an additional 8 weeks of follow-up. (A Study of the Efficacy and Safety of MK-0616 [Oral PCSK9 Inhibitor] in Adults With Hypercholesterolemia [MK-0616-008]; NCT05261126).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Ballantyne CM, Banka P, Mendez G, et al. Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616. J Am Coll Cardiol. 2023. PMID: 36889610. doi:10.1016/j.jacc.2023.02.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。